Ally Bridge (ny) is an investment fund managing more than $168 billion ran by Fan Yu. There are currently 25 companies in Yu’s portfolio. The largest investments include Soleno Therapeutics Inc and Sarepta Therapeutics Inc, together worth $23.3 billion.
As of 7th August 2024, Ally Bridge (ny)’s top holding is 286,162 shares of Soleno Therapeutics Inc currently worth over $11.7 billion and making up 7.0% of the portfolio value.
Relative to the number of outstanding shares of Soleno Therapeutics Inc, Ally Bridge (ny) owns more than approximately 0.1% of the company.
In addition, the fund holds 73,500 shares of Sarepta Therapeutics Inc worth $11.6 billion, whose value grew 7.4% in the past six months.
The third-largest holding is Geron worth $11.6 billion and the next is Merus N.V worth $10.3 billion, with 174,844 shares owned.
Currently, Ally Bridge (ny)'s portfolio is worth at least $168 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Ally Bridge (ny) office and employees reside in New York, New York. According to the last 13-F report filed with the SEC, Fan Yu serves as the Director at Ally Bridge (ny).
In the most recent 13F filing, Ally Bridge (ny) revealed that it had opened a new position in
Sarepta Therapeutics Inc and bought 73,500 shares worth $11.6 billion.
This means they effectively own approximately 0.1% of the company.
Sarepta Therapeutics Inc makes up
11.9%
of the fund's Health Care sector allocation and has grown its share price by 18.7% in the past year.
The investment fund also strengthened its position in Context Therapeutics Inc by buying
1,160,281 additional shares.
This makes their stake in Context Therapeutics Inc total 1,886,232 shares worth $3.78 billion.
On the other hand, there are companies that Ally Bridge (ny) is getting rid of from its portfolio.
Ally Bridge (ny) closed its position in Verona Pharma Plc on 14th August 2024.
It sold the previously owned 736,738 shares for $11.9 billion.
Fan Yu also disclosed a decreased stake in Soleno Therapeutics Inc by 0.1%.
This leaves the value of the investment at $11.7 billion and 286,162 shares.
The two most similar investment funds to Ally Bridge (ny) are Aspect Partners and Cahill Wealth Management. They manage $168 billion and $168 billion respectively.
Ally Bridge (ny)’s portfolio is diversified across 3 sectors.
Currently, their heaviest sector is Health Care — making up 58.4% of
the total portfolio value.
The fund focuses on investments in the United States as
40.0% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
16% of the total holdings value.
On the other hand, large-cap stocks make up only 4.0% of the portfolio.
The average market cap of the portfolio companies is close to $2.23 billion.
These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Verona Pharma Plc |
Closed
736,738
|
$11,854,114,000 | |
| Soleno Therapeutics Inc |
14.96%
286,162
|
$11,675,410,000 | 6.96% |
| Sarepta Therapeutics Inc |
Opened
73,500
|
$11,613,000,000 | 6.92% |
| Geron Corp. |
0.86%
2,736,663
|
$11,603,451,000 | 6.91% |
| Merus N.V |
31.68%
174,844
|
$10,345,519,000 | 6.16% |
| Avadel Pharmaceuticals plc |
Closed
547,036
|
$9,239,438,000 | |
| Insmed Inc |
48.40%
129,000
|
$8,643,000,000 | 5.15% |
| Legend Biotech Corp |
Opened
195,000
|
$8,636,550,000 | 5.15% |
| Alumis Inc |
Opened
618,750
|
$8,229,375,000 | 4.90% |
| Blueprint Medicines Corp |
53.01%
75,638
|
$8,152,264,000 | 4.86% |
| Disc Medicine Inc |
Opened
166,500
|
$7,504,155,000 | 4.47% |
| Day One Biopharmaceuticals I |
Opened
536,095
|
$7,387,389,000 | 4.40% |
| Mind Medicine Mindmed Inc |
3.60%
965,426
|
$6,960,721,000 | 4.15% |
| Xenon Pharmaceuticals Inc |
45.25%
169,369
|
$6,603,697,000 | 3.93% |
| Dianthus Therapeutics Inc |
Closed
216,968
|
$6,509,040,000 | |
| Praxis Precision Medicines I |
3.83%
153,379
|
$6,343,755,000 | 3.78% |
| Olema Pharmaceuticals, Inc. |
Closed
559,035
|
$6,328,276,000 | |
| Kura Oncology Inc |
15.97%
306,762
|
$6,316,230,000 | 3.76% |
| Lyra Therapeutics, Inc. |
Closed
1,003,741
|
$6,243,269,000 | |
| Avadel Pharmaceuticals plc |
Opened
430,245
|
$6,049,245,000 | 3.60% |
| Longboard Pharmaceuticals In |
19.06%
218,981
|
$5,919,056,000 | 3.53% |
| Cg Oncology Inc |
45.42%
174,876
|
$5,520,835,000 | 3.29% |
| Jasper Therapeutics Inc |
24.60%
218,614
|
$4,962,538,000 | 2.96% |
| Trevi Therapeutics, Inc. |
Opened
1,474,926
|
$4,395,279,000 | 2.62% |
| Tyra Biosciences Inc |
Opened
264,660
|
$4,231,913,000 | 2.52% |
| Perspective Therapeutics Inc |
Opened
396,242
|
$3,950,533,000 | 2.35% |
| Black Diamond Therapeutics I |
Opened
835,000
|
$3,891,100,000 | 2.32% |
| Context Therapeutics Inc |
159.83%
1,886,232
|
$3,781,895,000 | 2.25% |
| RAPT Therapeutics, Inc. |
Closed
420,000
|
$3,771,600,000 | |
| Mersana Therapeutics Inc |
Closed
801,437
|
$3,590,438,000 | |
| Marinus Pharmaceuticals Inc |
Closed
394,773
|
$3,568,748,000 | |
| Eliem Therapeutics Inc |
Opened
500,000
|
$3,555,000,000 | 2.12% |
| Promis Neurosciences Inc |
No change
1,059,582
|
$1,589,373,000 | 0.95% |
| No transactions found | |||
| Showing first 500 out of 33 holdings | |||